Risk of endometrial cancer following estrogen replacement with and without progestins.
BACKGROUND
Unopposed estrogen replacement therapy (i.e., estrogen without progestins) increases the risk of endometrial cancer. In this study, we examined the endometrial cancer risk associated with combined estrogen-progestin regimens currently in use, since the safety profiles of these regimens have not been clearly defined.


METHODS
We conducted a nationwide population-based, case-control study in Sweden of postmenopausal women aged 50-74 years. We collected information on use of hormone replacement from 709 case patients with incident endometrial cancer and from 3368 control subjects. We used unconditional logistic regression to calculate odds ratios (ORs) as estimates of relative risks. All individual comparisons were made with women who never used the respective hormone replacement regimens.


RESULTS
Treatment with estrogens alone was associated with a marked duration- and dose-dependent increase in the relative risk of endometrial cancer. Five or more years of treatment had an OR of 6.2 for estradiol (95% confidence interval [CI] = 3.1-12.6) and of 6.6 for conjugated estrogens (95% CI = 3.6-12.0). Following combined estrogen-progestin use, the association was considerably weaker than that for estrogen alone; the OR was 1.6 (95% CI = 1.1-2.4) after 5 or more years of use. This increase in risk was confined to women with cyclic use of progestins, i.e., fewer than 16 days per cycle (most commonly 10 days per cycle [OR = 2.9; 95% CI = 1.8-4.6 for 5 or more years of use]), whereas continuous progestin use along with estrogens was associated with a reduced risk (OR = 0.2; 95% CI = 0.1-0.8 for 5 or more years of use).


CONCLUSIONS
The risk of developing endometrial cancer is increased after long-term use of estrogens without progestins and with cyclically added progestins. Continuously added progestins may be needed to minimize the endometrial cancer risk associated with estrogen replacement therapy.
Weiderpass
E
E
Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden. Elisabete.Weiderpass@mep.ki.se
Adami
H O
HO
Baron
J A
JA
Magnusson
C
C
Bergström
R
R
Lindgren
A
A
Correia
N
N
Persson
I
I
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000473:pathology; D000368:Aged; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000473:pathology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000379:methods*; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D016017:Odds Ratio; D011372:Progestins / Q000627:therapeutic use*; D012306:Risk; D012307:Risk Factors; D013548:Sweden; D013997:Time Factors
D004967:Estrogens; D011372:Progestins